Status:
COMPLETED
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
Lead Sponsor:
Novartis
Conditions:
Kidney Transplantation
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The purpose of the study in de novo renal transplant patients is to evaluate the effect on renal function of an optimized new regimen in comparison with the standard everolimus exposure plus a low-dos...
Eligibility Criteria
Inclusion
- Recipients of deceased, living unrelated, or non-human leukocyte antigen (HLA) identical living related donor renal transplant who actually have a viable kidney transplant at the time of randomization (within 24 hours of graft reperfusion)
- The renal cold ischemic time must be \< 36 hours.
- The age of the donor must be between 15 and 65 years.
Exclusion
- Patients who are recipients of multiple organ transplants, including more than one kidney
- Patients who have previously received an organ transplant which failed within one year
- Patients with current panel reactive T-cell antibody titers of 50% or more
- Patients who are recipients of A-B-O incompatible transplants or T-cell crossmatch positive transplant
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
July 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00170885
Start Date
May 1 2005
End Date
July 1 2007
Last Update
November 16 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
Basel, Switzerland